The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

Bonten, M. J. M., Huijts, S. M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., van Werkhoven, C. H., van Deursen, A. M. M., Sanders, E. A. M., Verheij, T. J. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408544 · Cited by 1,248 · see citing works

The aging of the immune system

Weiskopf, D., Weinberger, B., & Grubeck-Loebenstein, B. (2009) · Transplant International · doi:10.1111/j.1432-2277.2009.00927.x · Cited by 908 · see citing works

B-cell responses to vaccination at the extremes of age

Siegrist, C.-A., & Aspinall, R. (2009) · Nature Reviews Immunology · doi:10.1038/nri2508 · Cited by 659 · see citing works

Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans

Solana, R., Tarazona, R., Gayoso, I., Lesur, O., Dupuis, G., & Fulop, T. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.04.008 · Cited by 567 · see citing works

Reduction in Functional Antibody Activity Against Streptococcus pneumoniae in Vaccinated Elderly Individuals Highly Correlates with Decreased IgG Antibody Avidity

Romero‐Steiner, S., Musher, D. M., Cetron, M. S., Pais, L. B., Groover, J. E., & Carlone, G. M. (1999) · Clinical Infectious Diseases · doi:10.1086/520200 · Cited by 311 · see citing works

Age effects on B cells and humoral immunity in humans

Frasca, D., Diaz, A., Romero, M., Landin, A. M., & Blomberg, B. B. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.08.004 · Cited by 271 · see citing works

Comparison of Pneumococcal Conjugate Polysaccharide and Free Polysaccharide Vaccines in Elderly Adults: Conjugate Vaccine Elicits Improved Antibacterial Immune Responses and Immunological Memory

Roux, A. D., Schmöele-Thoma, B., Siber, G. R., Hackell, J. G., Kuhnke, A., Ahlers, N., BAKER, S. A., Razmpour, A., Emini, E. A., Fernsten, P. D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/529142 · Cited by 268 · see citing works

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

Jackson, L. A., Gurtman, A., van Cleeff, M., Jansen, K. U., Jayawardene, D. A., Devlin, C., Scott, D. A., Emini, E. A., Gruber, W. C., & Schmöele-Thoma, B. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.04.085 · Cited by 232 · see citing works

Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia

Huijts, S. M., Pride, M. W., Vos, J. M. I., Jansen, K. U., Webber, C., Gruber, W. C., Boersma, W. G., Snijders, D., Kluytmans, J. A. J. W., van der Lee, I., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00137412 · Cited by 72 · see citing works

High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees

Vermeiren, A. P. A., Hoebe, C. J. P. A., & Dukers–Muijrers, N. H. T. M. (2013) · Journal of Clinical Virology · doi:10.1016/j.jcv.2013.07.003 · Cited by 69 · see citing works

A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly

MacIntyre, C. R., Ridda, I., Gao, Z., Moa, A., McIntyre, P. B., Sullivan, J. S., Jones, T. R., Hayen, A. D., & Lindley, R. I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094578 · Cited by 41 · see citing works

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial

Dbaibo, G. S., El-Ayoubi, N. K., Ghanem, S., Hajar, F., Bianco, V., Miller, J. M., & Mesaros, N. E. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0065-0 · Cited by 37 · see citing works

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791 · see citing works

Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?

Bajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H., & Moulton, V. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.571416 · Cited by 476 · see citing works

Aging of the immune system: Focus on inflammation and vaccination

Pinti, M., Appay, V., Campisi, J., Frasca, D., Fülöp, T., Sauce, D., Larbi, A., Weinberger, B., & Cossarizza, A. (2016) · European Journal of Immunology · doi:10.1002/eji.201546178 · Cited by 439 · see citing works

Influence of immune aging on vaccine responses

Gustafson, C. E., Kim, C., Weyand, C. M., & Goronzy, J. J. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.03.017 · Cited by 286 · see citing works

Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults

Falsey, A. R., Williams, K. L., Gymnopoulou, E., Bart, S., Ervin, J. E., Bastian, A. R., Menten, J., Paepe, E. D., Vandenberghe, S., Chan, E. K. H., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2207566 · Cited by 154 · see citing works

Overcoming immune dysfunction in the elderly: trained immunity as a novel approach

Bulut, O., Kilic, G., Domínguez-Andrés, J., & Netea, M. G. (2020) · International Immunology · doi:10.1093/intimm/dxaa052 · Cited by 99 · see citing works

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance

Scelfo, C., Menzella, F., Fontana, M. S., Ghidoni, G., Galeone, C., & Facciolongo, N. C. (2021) · Vaccines · doi:10.3390/vaccines9050420 · Cited by 90 · see citing works

A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults)

Patterson, S., Webber, C., Patton, M., Drews, W., Huijts, S. M., Bolkenbaas, M., Gruber, W. C., Scott, D. A., & Bonten, M. J. M. (2016) · Trials in Vaccinology · doi:10.1016/j.trivac.2016.04.004 · Cited by 78 · see citing works

The full benefits of adult pneumococcal vaccination: A systematic review

Cafiero-Fonseca, E. T., Stawasz, A., Johnson, S. T., Sato, R., & Bloom, D. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186903 · Cited by 60 · see citing works

Distribution and reference interval establishment of neutral‐to‐lymphocyte ratio (NLR), lymphocyte‐to‐monocyte ratio (LMR), and platelet‐to‐lymphocyte ratio (PLR) in Chinese healthy adults

Wang, J., Zhang, F., Jiang, F., Hu, L., Chen, J., & Wang, Y. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23935 · Cited by 54 · see citing works

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

van Deursen, A. M. M., van Houten, M. A., Webber, C., Patton, M., Scott, D. A., Patterson, S., Sidhu, M. S., Drews, W., Gruber, W. C., Emini, E. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix419 · Cited by 49 · see citing works

Pneumococcal vaccination and chronic respiratory diseases

Froes, F., Roche, N., & Blasi, F. (2017) · International Journal of COPD · doi:10.2147/copd.s140378 · Cited by 49 · see citing works

Reference Values for Neutrophil to Lymphocyte Ratio (NLR), a Biomarker of Cardiovascular Risk, According to Age and Sex in a Latin American Population

Huguet, E., Maccallini, G., Pardini, P., Hidalgo, M., Obregon, S., Botto, F. O., Koretzky, M., Nilsson, P. M., Ferdinand, K. C., & Kotliar, C. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2019.04.002 · Cited by 48 · see citing works

Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old

Nicoli, F., Clave, E., Wanke, K., von Braun, A., Bondet, V., Alanio, C., Douay, C., Baqué, M., Lependu, C., Marconi, P., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103852 · Cited by 41 · see citing works

Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands

de Boer, P. T., van Werkhoven, C. H., van Hoek, A. J., Knol, M. J., Sanders, E. A. M., Wallinga, J., de Melker, H. E., & Steens, A. (2024) · BMC Medicine · doi:10.1186/s12916-024-03277-3 · Cited by 39 · see citing works

Pneumococcal Capsular Polysaccharide Immunity in the Elderly

Adler, H., Ferreira, D. M., Gordon, S. B., & Rylance, J. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00004-17 · Cited by 39 · see citing works

Pneumococcal Pneumonia and Invasive Pneumococcal Disease in Those 65 and Older: Rates of Detection, Risk Factors, Vaccine Effectiveness, Hospitalisation and Mortality

Thomas, R. E. (2021) · Geriatrics · doi:10.3390/geriatrics6010013 · Cited by 31 · see citing works

PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Theilacker, C., Fletcher, M. A., Jódar, L., & Gessner, B. D. (2022) · Microorganisms · doi:10.3390/microorganisms10010127 · Cited by 31 · see citing works

Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium

Willem, L., Blommaert, A., Hanquet, G., Thiry, N., Bilcke, J., Theeten, H., Verhaegen, J., Goossens, H., & Beutels, P. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1428507 · Cited by 29 · see citing works

Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial

Ceccato, A., Cillóniz, C., Ranzani, O., Menéndez, R., Agustı́, C., Gabarrús, A., Ferrer, M., Sibila, O., Niederman, M. S., & Torres, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178022 · Cited by 29 · see citing works

SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom

Williams, G. H., Llewelyn, A., Brandão, R. A. R., Chowdhary, K., Hardisty, K.-M., & Loddo, M. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101021 · Cited by 26 · see citing works

Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions

Treskova, M., Scholz, S. M., & Kuhlmann, A. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00805-5 · Cited by 26 · see citing works

Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant

Musher, D. M., & Rodriguez‐Barradas, M. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1098794 · Cited by 25 · see citing works

Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany

Deb, A., Podmore, B., Barnett, R., Beier, D., Galetzka, W., Qizilbash, N., Häckl, D., Mihm, S., Johnson, K. D., & Weiss, T. W. (2022) · Epidemiology and Infection · doi:10.1017/s0950268822001182 · Cited by 25 · see citing works

The epidemiologic and biologic basis for classifying older age as a high-risk, immunocompromising condition for pneumococcal vaccine policy

Grant, L. R., Slack, M., Yan, Q., Trzciński, K., Barratt, J., Sobczyk, E. A., Appleby, J. C., Cane, A. D., Jódar, L., Istúriz, R., et al. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1921579 · Cited by 22 · see citing works

The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value

Janssens, E., Flamaing, J., Vandermeulen, C., Peetermans, W. E., Desmet, S., & Munter, P. D. (2022) · Acta Clinica Belgica · doi:10.1080/17843286.2022.2039865 · Cited by 22 · see citing works

Efficacy and Safety of Vaccinations in Geriatric Patients: A Literature Review

Ciarambino, T., Crispino, P., Buono, P., Giordano, V., Trama, U., Iodice, V., Leoncini, L., & Giordano, M. (2023) · Vaccines · doi:10.3390/vaccines11091412 · Cited by 24 · see citing works

Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia

Karlsson, J., Roalfe, L., Hogevik, H., Zancolli, M., Andréasson, B., Goldblatt, D., & Wennerås, C. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00654-15 · Cited by 22 · see citing works

Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial

van der Heiden, M., Shetty, S. A., Bijvank, E., Beckers, L., Çevirgel, A., van Sleen, Y., Tcherniaeva, I., Ollinger, T., Burny, W., van Binnendijk, R. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50760-9 · Cited by 21 · see citing works

The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia

Chen, C., Wood, J., Beutels, P., Menzies, R., MacIntyre, C. R., Dirmesropian, S., Reyes, J. F., McIntyre, P. B., & Newall, A. T. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.01.052 · Cited by 21 · see citing works

Cost-effectiveness of pneumococcal vaccination for elderly in Sweden

Wolff, E., Storsæter, J., Örtqvist, Å., Nauclér, P., Larsson, S., Lepp, T., & Roth, A. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.072 · Cited by 19 · see citing works

Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study

van Werkhoven, C. H., Bolkenbaas, M., Huijts, S. M., Verheij, T. J., & Bonten, M. J. M. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.09.011 · Cited by 19 · see citing works

How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells

Garnica, M., Aiello, A., Ligotti, M. E., Accardi, G., Arasanz, H., Bocanegra, A., Blanco, E., Calabrò, A., Chocarro, L., Echaide, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179797 · Cited by 19 · see citing works

Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults

van der Heiden, M., Boots, A. M. H., Marinović, A. A. B., de Rond, L., van Maurik, M., Tcherniaeva, I., Berbers, G. A. M., & Buisman, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00817 · Cited by 17 · see citing works

Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada

Ximenes, R., Simmons, A. E., Gebretekle, G. B., Nam, A., Wong, E., Salvadori, M. I., Golden, A., Sander, B., Hildebrand, K. J., Tunis, M. C., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126985 · Cited by 17 · see citing works

Optimal age targeting for pneumococcal vaccination in older adults; a modelling study

Thindwa, D., Clifford, S., Kleynhans, J., von Gottberg, A., Walaza, S., Meiring, S. T., Swarthout, T. D., Miller, E., McIntyre, P. B., Andrews, N. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36624-8 · Cited by 15 · see citing works

Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection

Marbaix, S., Peetermans, W. E., Verhaegen, J., Annemans, L., Sato, R., Mignon, A., Atwood, M., & Weycker, D. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199427 · Cited by 14 · see citing works

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians

Dirmesropian, S., Wood, J., MacIntyre, C. R., Beutels, P., McIntyre, P. B., Menzies, R., Reyes, J. F., Chen, C., & Newall, A. T. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.06.085 · Cited by 13 · see citing works

Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions

Rosenthal, M., Stoecker, C., Leidner, A. J., Cho, B., Pilishvili, T., & Kobayashi, M. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126567 · Cited by 12 · see citing works

Immunofitness in the elderly: The role of vaccination in promoting healthy aging

Rial, J. G., Redondo, E., Calle, I. R., Mascarós, E., Ocaña, D., Jimeno, I., Gil, A., Linares, M., Onieva-García, M. Á., González‐Romo, F., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2624234 · Cited by 12 · see citing works

Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease

Walkowski, W., Bassett, J., Bhalla, M., Pfeifer, B. A., & Ghanem, E. N. B. (2021) · Vaccines · doi:10.3390/vaccines9060589 · Cited by 10 · see citing works

Correlation of the ratio of IgM/IgG concentration to days after symptom onset (IgM/T or IgG/T) with disease severity and outcome in non-critical COVID-19 patients.

Rong, Y., Wang, F., Li, X., Liang, X., Zhou, Y., Zhang, D., Liu, J., Zeng, H., Wang, J., & Shi, Y. (2021) · PubMed Central · Cited by 8 · see citing works

Liposomal Encapsulation of Polysaccharides (LEPS) as an Effective Vaccine Strategy to Protect Aged Hosts Against S. pneumoniae Infection

Bhalla, M., Nayerhoda, R., Tchalla, E. Y. I., Abamonte, A., Park, D., Simmons, S. R., Pfeifer, B. A., & Ghanem, E. N. B. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.798868 · Cited by 8 · see citing works

Pneumococcal infections in elderly patients attending hospital since PCV-13 authorization in Spain

Payeras, A., Peñaranda, M., Iñigo, A., Garau, M., Pérez, J. L., Gallegos, C., & Riera, M. (2016) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2016.1218044 · Cited by 8 · see citing works

Vaccination against Respiratory Infections in the Immunosenescent Older Adult Population: Challenges and Opportunities

Ecarnot, F., & Maggi, S. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2500-2121 · Cited by 6 · see citing works

Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway

Nymark, L. S., Berild, J. D., Lyngstad, T. M., Winje, B. A., Vestrheim, D. F., Aaberge, I., Juvet, L. K., & Wolff, E. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2101333 · Cited by 6 · see citing works

New MoDC-Targeting TNF Fusion Proteins Enhance Cyclic Di-GMP Vaccine Adjuvanticity in Middle-Aged and Aged Mice

Gogoi, H., Mansouri, S., Katikaneni, D. S., & Jin, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01674 · Cited by 5 · see citing works

Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions

Kobayashi, M., Stoecker, C., Xing, W., Cho, B., & Pilishvili, T. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1861876 · Cited by 5 · see citing works

Efficacy, immunogenicity, and evidence for best-timing of pneumococcal vaccination in splenectomized adults: a systematic review

Lenzing, E., Rezahosseini, O., Burgdorf, S. K., Nielsen, S. D., & Harboe, Z. B. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2049250 · Cited by 5 · see citing works

Age-related decline in IgM responses associate with reduced opsonophagocytic activity following PCV13 vaccination

Visser, M., van Beek, J., Tcherniaeva, I., van Rooijen, D. M., Beckers, L., Bijvank, E., de Jonge, M. I., Lockhart, S. P., Pride, M. W., Rots, N. Y., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01152-7 · Cited by 4 · see citing works

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data

Beeslaar, J. F., Peyrani, P., Absalon, J., Maguire, J. D., Eiden, J., Balmer, P., Maansson, R., & Perez, J. L. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00322-5 · Cited by 4 · see citing works

Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy

Fletcher, M. A., Schmöele-Thoma, B., Vojicic, J., Daigle, D., Paradiso, P. R., & Morales, G. D. C. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2404636 · Cited by 4 · see citing works

The lung bacterial microbiome in community-acquired and nosocomial pneumonia

Bos, L. D. J., Rylance, J., & Gordon, S. B. (2019) · European Respiratory Society eBooks · doi:10.1183/2312508x.10016418 · Cited by 4 · see citing works

What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?

Newall, A. T. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1197449 · Cited by 4 · see citing works

Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals

Whelan, M., Galipeau, Y., Habeeb, N. W.-A., Konforte, D., Hassan, M. A. E., Booth, R. A., Arnold, C. R., Langlois, M., & Pelchat, M. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad384 · Cited by 3 · see citing works

Global Burden of Pressure Ulcer and Contributing Factors from 1990 to 2021: A Systematic Analysis with Forecasts to 2035

Lei, H., Zhong, K., Chen, J., Li, P., Chen, J., Li, H., Cheng, B., & Zhou, J. (2025) · Advances in Wound Care · doi:10.1089/wound.2025.0021 · Cited by 3 · see citing works

Pneumococcal conjugate vaccines in older adults and immunocompromised individuals

Luvira, V., Ngamprasertchai, T., & Pitisuttithum, P. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2602525 · Cited by 2 · see citing works

Economic analysis of 15-valent and 20-valent pneumococcal conjugate vaccines among older adults in Ontario, Canada

Gebretekle, G. B., O’Reilly, R., Mac, S., Fadel, S. A., Crowcroft, N. S., & Sander, B. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2488495 · Cited by 2 · see citing works

Constrained Optimization for Pneumococcal Vaccination in Brazil

Olbrecht, J., Gomez, J. A., Bellinghen, L.-A. V., Vlaenderen, I. V., & Standaert, B. A. (2021) · Value in Health Regional Issues · doi:10.1016/j.vhri.2020.11.011 · Cited by 2 · see citing works

The role of pneumococcal vaccination in reducing cardiovascular risk in cardiac patients: Expert opinion of the Prevention Committee of the Polish Cardiac Society supported by the Polish Vaccinology Society

Mamcarz, A., Wełnicki, M. T., Dróżdż, J., Grabowski, M., Jankowski, P., Kuchar, E. P., Leszek, P., Mitkowski, P. P., & Wysocki, J. (2023) · Kardiologia Polska · doi:10.33963/v.kp.96718 · Cited by 2 · see citing works

Global, regional, and national burden of bacterial carbapenem resistance from 1990 to 2021 and predictions up to 2035

Tai, J.-H., Lyu, Y.-Y., Zhang, Y., Chu, W.-W., Yang, M. C., Zhou, Q., & Wu, Y. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107636 · Cited by 1 · see citing works

Intranasal vaccination with probiotic Escherichia coli membrane vesicles displaying pneumococcal capsular polysaccharides elicits mucosal immunity

Nakao, R., Kimura, S., Abe, K., Yamaguchi, T., Kuroda, E., Hamaguchi, S., Tateda, K., Ohki, Y., Narisawa, N., Ohnishi, M., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01345-0 · Cited by 1 · see citing works

The prostaglandin D2 antagonist asapiprant ameliorates clinical severity in young hosts infected with invasive Streptococcus pneumoniae

Bhalla, M., Herring, S. E., Lenhard, A. P., Wheeler, J., Aswad, F., Klumpp, K., Rebo, J., Wang, Y., Wilhelmsen, K., Fortney, K., et al. (2024) · Infection and Immunity · doi:10.1128/iai.00522-23 · Cited by 1 · see citing works

Resposta imunológica vacinal na população geriátrica: duração e efetividade

Camargo, R. P., Nascimento, T. A., Ferreira, M. V. M., Paz, C. V. D. A., Malacarne, L. P., de Sousa, E. G., Pegoraro, F., & Gomes, S. T. M. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-301 · Cited by 1 · see citing works

Multiple vaccine comparison in the same adults from the VITAL study reveals vaccine-specific and age-related humoral response patternsPreprint

van der Heiden, M., Shetty, S. A., Bijvank, E., Beckers, L., Çevirgel, A., van Sleen, Y., Tcherniaeva, I., Ollinger, T., Burny, W., van Binnendijk, R. S., et al. (2024) · medRxiv · doi:10.1101/2024.01.22.24301601 · Cited by 1 · see citing works

Vacuna neumocócica: «El camino del progreso no es ni rápido ni fácil»

Payeras, A., & Arrizabalaga, M. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2015.12.001

Neumococcal vaccine: “the road to progress is neither fast nor easy”

Payeras, A., & Arrizabalaga, M. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.05.032

Pneumokokkenimpfung mit PCV-13 für Senioren

Heppner, H. J. (2016) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-016-8572-7

Infectious immunity and pneumococcal vaccine responses in multiple myeloma and related disorders

Karlsson, J. (2016) · Gothenburg University Publications Electronic Archive (Gothenburg University)

Effects of Ageing on the Vaccination Response

Weinberger, B. (2016) · Springer eBooks · doi:10.1007/978-3-319-43365-3_5

Pneumococcal disease and the impact of pneumococcal conjugate vaccines

Wagenvoort, G. H. J. (2017) · Utrecht University Repository (Utrecht University)

Promotion of a Lifelong Immunization Program for Healthy Ageing

Flamaing, J. (2018) · Practical issues in geriatrics · doi:10.1007/978-3-319-96529-1_16

Pneumococcal Vaccines in Adults

Nanduri, S. A., Pilishvili, T., & Bennett, N. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55435-0.00012-4

Vaccination Against Pneumococcal Disease in the European Union, with Particular Focus on Germany

Falkenhorst, G., & Flamaing, J. (2019) · Practical issues in geriatrics · doi:10.1007/978-3-030-05159-4_11

Letter to the editor

Arguedas, A. G., Gessner, B. D., Williams, S., Fletcher, M. A., Istúriz, R., Reinert, R., & Jódar, L. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.09.107

Optimal age targeting for pneumococcal vaccination in older adults; a modelling studyPreprint

Thindwa, D., Clifford, S., Kleynhans, J., von Gottberg, A., Walaza, S., Meiring, S. T., Swarthout, T. D., Miller, E., McIntyre, P. B., Andrews, N. J., et al. (2022) · medRxiv · doi:10.1101/2022.11.07.22282045

Building on a Strong Foundation to Address a New Era to Help Protect Against Pneumococcal Disease

Science, I. M. A. (2022) · EMJ Microbiology & Infectious Diseases · doi:10.33590/emjmicrobiolinfectdis/10028394

Global Epidemiology of Multidrug-Resistant Lower Respiratory Infections in Adults ≥55 years: Trends (1990–2021) and Projections to 2050Preprint

Zhao, J., Li, G., Qiu, Y., Wang, Y., Huang, G., Gong, Y., Liu, J., & Shen, F. (2025) · Research Square · doi:10.21203/rs.3.rs-7950784/v1

Additional file 1 of Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands

de Boer, P. T., van Werkhoven, C. H., Hoek, A. J. V., Knol, M. J., Sanders, E. A. M., Wallinga, J., de Melker, H. E., & Steens, A. (2024) · Figshare · doi:10.6084/m9.figshare.25231181

Cost-effectiveness analysis of expanding the adult pneumococcal vaccination recommendations to include adults aged 50 years and older in the United States

Bletnitsky, S., Leidner, A. J., Kobayashi, M., Cho, B., & Stoecker, C. (2026) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2026.108412

109913-valent Pneumococcal Conjugate Vaccine Efficacy is Declining with Old Age: Results from an Exploratory Analysis of the CAPiTA Trial

van Werkhoven, C. H., Huijts, S. M., Bolkenbaas, M., Webber, C., Schmöele-Thoma, B., Patterson, S. D., Gruber, W. C., Grobbee, D. E., & Bonten, M. J. M. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu052.807 · Cited by 6 · see citing works

PCV13: Effective Against First-Episode CAP in Older Adults

Lawrence, L. (2015)

Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults

Istúriz, R., & Webber, C. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1043502 · Cited by 22 · see citing works

High effectiveness of PCV13 Vaccine to Prevent Community-Acquired Pneumonia in Adults over 65

Lopardo, G. D., Vizzotti, C., Giglio, N., Raimondo, E., Fridman, D., Micone, P., Gonzalez, M., & Stamboulián, D. (2018) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.04.4218

PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Theilacker, C., Fletcher, M. A., Jódar, L., & Gessner, B. D. (2022) · Microorganisms · doi:10.3390/microorganisms10010127 · Cited by 31 · see citing works